MetaCap

Lycia Therapeutics (LYCA) vs Vir Biotechnology (VIR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lycia Therapeutics is the larger company by market cap ($1.72 billion vs $1.56 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LYCA+10.23%VIR-20.62%
+32%+4%-23%
Oct 23, 20261 yearNov 20, 2026
LYCA+10.23%VIR-20.62%
+17%-3%-22%
Oct 19, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LYCA versus VIR key metrics
MetricLYCAVIR
Share price$33.07$8.39
Market cap$1.72B$1.56B
1-day change+4.09%-5.41%
YTD return—+39.14%
1-year return—+47.71%
5-year return—-76.69%
EPS (TTM)$-1.04$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$68.56M
Revenue growth (YoY)—-7.61%
Net income (latest FY)—$-437.99M
Gross margin—99.96%
Operating margin—-699.18%
Net margin—-638.87%
52-week high$36.49$14.38
52-week low$22.19$5.45
Distance from 52-week high-9.37%-41.66%
Analyst consensus—strong_buy
Avg. price target upside—+178.67%
Average volume432.72K2.45M
Shares outstanding52.09M186.27M
Employees31367
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lycia Therapeutics

LYCA stock →

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees

About Vir Biotechnology

VIR stock →

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees

LYCA vs VIR FAQ

Which is bigger, Lycia Therapeutics or Vir Biotechnology?

Lycia Therapeutics (LYCA) is larger, with a market capitalization of $1.72B compared with $1.56B for Vir Biotechnology (VIR).

Are Lycia Therapeutics and Vir Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons